Puma Biotechnology – A New Drug on the Horizon for HER2 Breast Cancer Patients
Puma Biotechnology (NASDAQ: PBYI), a biopharmaceutical company focused on Oncology, announced the submission of a supplemental New Drug Application (sNDA) to the FDA, for neratinib in combination with capecitabine for treatment of HER2-positive metastatic breast cancer in patients who have failed two or more prior...
